Viable mouse models of acid β-glucosidase deficiency -: The defect in Gaucher disease

被引:143
作者
Xu, YH
Quinn, B
Witte, D
Grabowski, GA
机构
[1] Cincinnati Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp Res Fdn, Div Pathol, Cincinnati, OH 45229 USA
关键词
D O I
10.1016/S0002-9440(10)63566-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Gaucher disease is an autosomal recessively inherited disease caused by mutations at the acid beta-glucosidase (G,Case) locus (GBA). To develop viable models of Gaucher disease, point mutations (pmuts), encoding N370S, V394L, D409H, or D409V were introduced into the mouse GCase (gba) locus. DNA sequencing verified each unique pmut. Mutant GCase mRNAs were near wild-type (WT) levels. GCase activities were reduced to 2 to 25% of WT in liver, lung, spleen, and cultured fibroblasts from pmut/pmut or pmut/null mice. The corresponding brain GCase activities were similar to25% of WT. N370S homozygosity was lethal in the neonatal period. For the other pmut mice, a few storage cells appeared in the spleen at : 17 months (D409H or D409V homozygotes) or greater than or equal to1 year (V394L homozygotes). V394L/null, D409H/null, or D409V/null mice showed scattered storage cells in spleen at similar to3 to 4 months. Occasional storage cells (sinusoidal cells) were present in liver. In D409V/null mice, large numbers of Mac-3-positive storage cells (le, macrophages) accumulated in the lung. Glycosphingolipid analyses showed varying rates of progressive glucosylceramide accumulation in visceral organs of pmut/pmut or pmut/null mice, but not in brain. These GCase-deficient mice pro-vide tools for gaining insight into the pathophysiology of Gaucher disease and developing improved therapies.
引用
收藏
页码:2093 / 2101
页数:9
相关论文
共 47 条
[1]   GAUCHERS-DISEASE VARIANT CHARACTERIZED BY PROGRESSIVE CALCIFICATION OF HEART-VALVES AND UNIQUE GENOTYPE [J].
ABRAHAMOV, A ;
ELSTEIN, D ;
GROSSTSUR, V ;
FARBER, B ;
GLASER, Y ;
HADASHALPERN, I ;
RONEN, S ;
TAFAKJDI, M ;
HOROWITZ, M ;
ZIMRAN, A .
LANCET, 1995, 346 (8981) :1000-1003
[2]  
ADACHI M, 1967, ARCH PATHOL, V83, P513
[3]  
Ausubel F.M., 1992, CURRENT PROTOCOLS MO
[4]  
Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
[5]   GAUCHER DISEASE - NORRBOTTNIAN TYPE - NEURODEVELOPMENTAL, NEUROLOGICAL, AND NEUROPHYSIOLOGICAL ASPECTS [J].
BLOM, S ;
ERIKSON, A .
EUROPEAN JOURNAL OF PEDIATRICS, 1983, 140 (04) :316-322
[6]   The Gaucher registry -: Demographics and disease characteristics of 1698 patients with Gaucher disease [J].
Charrow, J ;
Andersson, HC ;
Kaplan, P ;
Kolodny, EH ;
Mistry, P ;
Pastores, G ;
Rosenbloom, BE ;
Scott, CR ;
Wappner, RS ;
Weinreb, NJ ;
Zimran, A .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (18) :2835-2843
[7]   Murine mucopolysaccharidosis type I: Targeted disruption of the murine alpha-L-iduronidase gene [J].
Clarke, LA ;
Russell, CS ;
Pownall, S ;
Warrington, CL ;
Borowski, A ;
Dimmick, JE ;
Toone, J ;
Jirik, FR .
HUMAN MOLECULAR GENETICS, 1997, 6 (04) :503-511
[8]   NEUROPATHOLOGY OF THE NORRBOTTNIAN TYPE OF GAUCHER DISEASE - MORPHOLOGICAL AND BIOCHEMICAL-STUDIES [J].
CONRADI, NG ;
SOURANDER, P ;
NILSSON, O ;
SVENNERHOLM, L ;
ERIKSON, A .
ACTA NEUROPATHOLOGICA, 1984, 65 (02) :99-109
[9]   PARTIAL ENZYME DEFICIENCIES - RESIDUAL ACTIVITIES AND THE DEVELOPMENT OF NEUROLOGICAL DISORDERS [J].
CONZELMANN, E ;
SANDHOFF, K .
DEVELOPMENTAL NEUROSCIENCE, 1984, 6 (01) :58-71
[10]  
DAHL N, 1990, AM J HUM GENET, V47, P275